Tumores Mamários

Impacto do câncer residual após quimioterapia neoadjuvante e desfechos de sobrevida de longo prazo no câncer de mama: análise multicêntrica de 5.161 pacientes.

4 Fev, 2022 | 15:42h

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients – The Lancet Oncology

Comentário: Long-Term Outcomes According to Residual Cancer Burden After Neoadjuvant Chemotherapy for Breast Cancer – The ASCO Post

Estudo observacional | Mastectomia e dissecção de linfonodos axilares feitas sem internação e com alta no dia seguinte parecem seguras para a maioria dos pacientes com câncer de mama.

4 Fev, 2022 | 14:53h

Same-day mastectomy and axillary lymph node dissection is safe for most patients with breast cancer – Journal of Surgical Oncology

Estudo MINDACT | Desfecho de pacientes com câncer de mama com risco ultrabaixo em painel genético.

25 Jan, 2022 | 11:36h

Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

Conteúdos relacionados:

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer – New England Journal of Medicine

Comentário no Twitter:

In MINDACT, 15% of the pts (n=1000) had an ultra-low 70-gene signature. Although some had tumors >2 cm (20%) & were LN+ (20%), prognosis was outstanding

8-year DMFI 97%
8-year BCSS 99.6%

Most of these patients received adj treatment. Did they need it?https://t.co/V9SH2StuQE

— Paolo Tarantino (@PTarantinoMD) January 22, 2022

Uso de bisfosfonatos adjuvantes e outros agentes modificadores ósseos no câncer de mama: atualização da diretriz ASCO-OH (CCO).

20 Jan, 2022 | 22:52h

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update – Journal of Clinical Oncology

Comentário no Twitter

Out on @JCO_ASCO the new ASCO/OH guidelines for adjuvant bisphosphonates in BC

Important to weight risks and benefits based on the risk profile of the disease, financial toxicity, drug availability, patient preferences, comorbidities & life expectancy. https://t.co/6noyYplALB

— Paolo Tarantino (@PTarantinoMD) January 18, 2022

M-A | Betabloqueadores e inibidores do sistema renina-angiotensina podem propiciar um benefício modesto para a preservação da função ventricular esquerda em pacientes com câncer de mama tratado com antraciclinas ou trastuzumabe.

20 Jan, 2022 | 21:59h

A systematic review and meta-analysis of beta-blockers and renin–angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer – European Journal of Cardiology (link para o resumo – $ para o texto completo)

Comentário: BBs, ACEI/ARBs to Prevent LV Dysfunction Due to Breast Cancer Drugs – American College of Cardiology

Capecitabina adjuvante para câncer de mama de início precoce: resultados de um estudo randomizado da sobrevida geral de 15 anos.

20 Jan, 2022 | 20:32h

Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial – Journal of Clinical Oncology

Análise final da sobrevida geral do estudo randomizado HER2CLIMB: tucatinibe vs. placebo adicionado a trastuzumabe e capecitabina para pacientes com câncer de mama metastático HER2+ tratado previamente com ou sem metástases cerebrais.

13 Jan, 2022 | 20:42h

Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis – Annals of Oncology (link para o resumo – $ para o texto completo)

Estudo original: Randomized Trial: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Estudo randomizado | Em pacientes com câncer de mama metastático, a terapia locorregional precoce para o sítio primário não melhorou a sobrevida ou a qualidade de vida.

12 Jan, 2022 | 12:45h

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108) – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

Estudo randomizado | Em mulheres na pré-menopausa com câncer de mama, análogos do hormônio liberador de gonadotropina podem preservar a função ovariana contra os efeitos gonadotóxicos induzidos pela quimioterapia.

12 Jan, 2022 | 12:44h

Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial – JAMA Oncology (link para o resumo – $ para o texto completo)

Comentário no Twitter

Randomized clinical trial finds administration of gonadotropin-releasing hormone analogs (GnRHa) with chemotherapy in premenopausal pts with #BreastCancer reduces risk of premature ovarian insufficiency (#POI) and promotes recovery of ovarian function. https://t.co/gymbKT9GWZ pic.twitter.com/OUOlIwPSsq

— JAMA Oncology (@JAMAOnc) December 30, 2021

Revisão sistemática | Benefícios e prejuízos do rastreamento mamográfico anual, bienal e trienal para mulheres na média de risco para câncer de mama.

9 Dez, 2021 | 15:20h

Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC) – British Journal of Cancer

Comentário no Twitter (fio – clique para saber mais)

Our comprehensive #systematicreview for the #ECIBC on intervals (every 1, 2, 3 years) of #breastcancer #screening is available.
We included RCT, observational, and mathematical modeling studies to assess benefits and harms and applied the #GRADE approachhttps://t.co/IfplsWfKuA pic.twitter.com/7niEbnaWKR

— Carlos Canelo-Aybar (@ccaneloa) November 27, 2021